29.7 C
Vientiane
Thursday, May 29, 2025
spot_img
Home Blog Page 360

The Gym Pod Launches in Hong Kong: Private, 24/7 App-Controlled Gyms

No More Excuses: Hong Kongers Can Now Book a Private Gym Session Anytime

HONG KONG, April 15, 2025 /PRNewswire/ — Imagine a gym where you never need to wait for equipment, don’t feel judged, and can work out any time of the day – even at 2 a.m. That’s the experience The Gym Pod is bringing to Hong Kong SAR.

After revolutionizing the fitness scene in Singapore with over 50 smart, private gym pods, The Gym Pod has launched two pods in Hong Kong – and they’re already turning heads. These unmanned micro gyms offer an entirely new way to train: private, on-demand, and fully app-controlled.

Privacy Meets Convenience

The Gym Pod was designed for busy, modern city-dwellers who want flexibility, privacy, and a frictionless fitness experience. Each pod is a self-contained gym space, available 24/7 and bookable in seconds through the The Gym Pod mobile app.

Inside, users will find everything they need – free weights, benches, resistance equipment, and even digital screens that guide beginners through workouts. Check out the equipment list and setup to see what’s inside each pod.

With sessions starting from just HK$38 per half hour, The Gym Pod is one of the most affordable private fitness options in the city – no contracts, no crowds, just you and your workout. Or users can bring a friend or two and further share the cost.

Breaking the Barriers to Fitness

“We found that many people feel intimidated at traditional gyms, or they simply don’t have time for crowded peak hours,” says Chris, Co-Founder of The Gym Pod Hong Kong. “We built this for those people – to make fitness as convenient and comfortable as ordering food delivery.”

With privacy, affordability, and tech at its core, The Gym Pod has built a loyal following in Singapore. Now, it’s ready to empower Hong Kongers to take charge of their fitness journeys.

Expanding Across Hong Kong

The Gym Pod is actively looking for new locations across Hong Kong and is calling on property owners, developers, and mall operators who want to unlock value in underutilized spaces.

“Our pods can go anywhere — rooftops, car parks, clubhouses — all we need is 25 square meters,” they add.

Interested in bringing The Gym Pod to your building or community? Visit our partnership and franchise page to learn more.

IQ-EQ enters the ANZ market with AMAL Group acquisition

Latest acquisition taps into growing demand for trustee and administration services in ANZ while strengthening the Group’s global presence

SYDNEY, April 15, 2025 /PRNewswire/ — IQ-EQ, an Astorg portfolio company, has signed an agreement to acquire the AMAL Group, a provider of Corporate Trust, Agency Services and Loan Servicing solutions with operations in Australia and New Zealand. The acquisition supports IQ-EQ’s strategy to expand its global corporate trust and loan servicing business and enter into key new growth markets.

This transaction is announced subject to regulatory approval from the Foreign Investment Review Board (FIRB) in Australia.

The acquisition takes place against the backdrop of accelerated growth in Australia’s corporate trust market due to strong continued year on year double digit growth in the securitisation market driven by regional growth in the non-bank lender (non-ADIs) market. With superannuation assets projected for 2025 to total $4.1 trillion and $11.5 billion in alternative investment flows we’re witnessing a significant shift driven by increased allocations to alternative assets such as infrastructure, real estate, and private equity. As interest rates ease private market fund managers are increasingly moving more into this market with high single digit growth expected across real assets and private credit and private equity. These market conditions are causing demand to rise for sophisticated, end-to-end trustee and loan administration solutions. 

As the region’s only integrated provider of loan servicing, corporate trust and agency services, AMAL Group has in excess of A$37 billion of funds under administration and supervision in Australia and New Zealand.                                                                                                

Commenting on the announcement, Mark Pesco, Group Chief Executive Officer at IQ-EQ said:

“This investment marks a significant milestone in our global expansion strategy, with an exciting opportunity to secure an important presence in two key new markets and take ownership of a leading corporate trustee, agency services and administration business.

“The AMAL Group’s addressable market spans the four key reporting segments of trustees – securitisation, wholesale loans, funds, and managed investment trusts, each of which have unique market dynamics and client requirements. As the only scaled end-to-end provider of trustee services and loan administration in Australia and New Zealand, this positions us to grow our corporate trust and loan administration business in synergy, cross-selling into our global client base and servicing our existing global clients amid growing demand for services in these new markets,” he added.

Richard Surrency, Group Chief Commercial Officer at IQ-EQ added:

“The AMAL Group brings deep client relationships, strong regulatory foundations, and market-recognised top-tier servicing capability to the table. Their highly experienced management team, full suite of licences, and proven technology infrastructure allows us to drive operational efficiencies, scale our offering, and accelerate growth across corporate trustee, loan administration and fund administration services. We’re particularly excited about the opportunity to build on its established track record in securitisation, and we hope to expand into adjacent areas over time.”

Chief Executive Officer of AMAL Trustees, Nick Procter further commented:

“Being part of a dynamic global player like IQ-EQ is a terrific market development that will enable AMAL to better service its existing clients and offer new products and services to a wider variety of markets and strategies. This transaction is good for everyone; for both businesses, for our clients and for the expert team of people who will help drive a smooth integration, business growth and success. We’re excited about what we can offer the Australian market and can’t wait to get started together.”

Following approval from the FIRB, AMAL Group will be rebranded to IQ-EQ, and the newly combined global IQ-EQ team will total 6,000 with an operational presence across 27 jurisdictions globally. The strategic acquisition of AMAL Group includes AMAL Asset Management Limited, AMAL Corporate Holdings Pty Limited and their subsidiaries collectively. Former principals of AMAL Group, Nick Procter and Tony Grant will continue to lead the business and will join the senior leadership team of IQ-EQ Asia ensuring continuity of the day-to-day delivery of services.

Leading global financial services group Nomura acted as financial adviser to IQ-EQ on this transaction.

Note to editors

About IQ-EQ

IQ-EQ is a global, top-tier investor services group with an unrivalled offering to meet the administration, compliance, and reporting needs of the investment sector in full and worldwide.

What makes us different is our people. Operating as trusted partners to our clients, we deliver intelligent solutions through a combination of well-honed technical expertise and strong relationships based on deep understanding. We’re driven by our Group purpose, to power people and possibilities.

We make life easier, more efficient and cost effective for our clients – be they fund managers, pension or sovereign wealth funds, multinational companies, or family offices – by providing everything in one place. Our services are underpinned by a Group-wide commitment to ESG and best-in-class technology including a global data platform and innovative proprietary tools supported by in-house experts.

Following this transaction, we’ll employ a global workforce of almost 6,000 people across 27 jurisdictions and have assets under administration (AUA) exceeding US$750 billion. We work with 13 of the world’s top 15 private equity firms. Also part of the IQ-EQ group of companies are First National Trustee Company, The Private Office and Agama.

To find out more about IQ-EQ visit iqeq.com

About Astorg

Astorg is a leading pan-European private equity firm with over €23 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance and capital they need to achieve their growth goals. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software, technology, business services and technology-based industrial companies. Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan. 

For more information about Astorg: www.astorg.com| Follow Astorg on LinkedIn

Contact:
Louise Veitch
Louise.veitch@aspectusgroup.com 

DXC Opens First Office in Toronto, Expanding North American Footprint

ASHBURN, Va., April 15, 2025 /PRNewswire/ — DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced the opening of its first Canadian sales center in the heart of Toronto. This milestone marks a significant step in DXC’s growth strategy and underscores the company’s commitment to talent, innovation, and customer success across Canada.

DXC Opens First Office in Toronto, Expanding North American Footprint
DXC Opens First Office in Toronto, Expanding North American Footprint

As Canada’s largest technology hub, Toronto offers access to top-tier talent, a thriving innovation ecosystem, and proximity to both new and long-standing clients. DXC has operated in Canada for over 20 years, with teams across all 10 provinces supporting more than 350 customers, such as CIBC, Aviva, TD, Manulife, Ivari, Federal Government, Ontario Pension Board, Elections Ontario, Mount Sinai Hospital, and Hitachi Construction Truck. Today, with more than 1,800 employees in Canada, DXC serves as a trusted operating partner and advisor for some of the most significant brands across financial services, healthcare, automotive, public sector and more, to help them thrive in the era of AI by modernizing operations and delivering cutting edge, transformative solutions.

“We’re thrilled to launch our first office in Toronto, the center of Canada’s business and tech community,” said Cameron Art, DXC President of the Americas and UKI. “This office is a clear signal of our long-term ambitions in the region, our commitment to collaborative innovation, and our focus on strengthening relationships with clients in this critical market.” 

The Toronto office joins DXC’s global network of collaboration spaces in major business districts around the world, designed to bring teams together and accelerate innovation. It also reflects DXC’s focus on solving digital transformation challenges — including AI, cybersecurity, and cloud. 

“With a world-class workforce and strong innovation ecosystem, Ontario continues to attract leading global companies, reinforcing our province’s position as a top destination for tech investment,” said The Honourable Victor Fedeli, Minister of Economic Development, Job Creation and Trade.  “We are pleased to welcome DXC Technology to Toronto and wish them continued success as they undertake this significant milestone in their operations.”

This is one of several strategic initiatives DXC is making across the Americas and UKI. The company is also expanding offices in New York City, Miami, and London, further enhancing its ability to serve clients and foster collaboration and co-creation.

DXC is a trusted operating partner to many of the world’s most innovative organizations, delivering services and solutions that drive industries and businesses forward. Our technology, engineering, and consulting experts help clients modernize systems, optimize processes, manage critical workloads, integrate AI-powered intelligence, and put security at the forefront.

For more information, visit www.dxc.com.

Health In Tech Announces First Quarter 2025 Financial Results

  • Revenues increased 56% over the first quarter 2024 to $8.0 million, reflecting strong market demand
  • Income before income taxes more than tripled to $0.7 million, up 257% over the first quarter 2024
  • Cash position remained strong at $7.6 million as of March 31, 2025

STUART, Fla., April 15, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced its financial results for the first quarter ended March 31, 2025.

Financial Highlights for the First Quarter of 2025

  • The number of enrolled employees (EEs) billed was 24,307, compared to 20,802 in the same period of 2024.
  • Total revenues were $8.0 million, 56% YoY growth.
  • Income before income tax expense was $0.7 million, 8.5% of revenue, compared to $0.2 million, 3.7% of revenue in the same period of 2024
  • Adjusted EBITDA was $1.2 million, compared to $0.5 million in the same period of 2024
  • Cash and cash equivalents were $7.6 million as of March 31, 2025, compared to $7.8 million as of December 31,2024.
  • Accounts receivable was $2.1 million as of March 31, 2025, with 28 days of AR days, compared to $1.6 million, 29 days of AR days as of December 31, 2024.

“We’re off to a strong start in 2025,” said Tim Johnson, CEO of Health In Tech. “First-quarter revenue grew 56% over the first quarter 2024, and income before income tax reached $0.7 million—8.5% of revenue—marking a 257% increase from the same period last year.”

“Our momentum continues to build post-IPO, validating the strategic initiatives we’ve executed. Innovations in our platform, product development, and market expansion are driving meaningful results and laying the groundwork for long-term growth. These gains reflect the strategic investments we made in 2024, particularly in product and service innovation, IT enhancements, infrastructure, cybersecurity, and internal controls. With these foundations in place, we’re now scaling efficiently and reaching a wider market.”

Tim continued: “Since beginning beta development of our large-group third-party AI-powered underwriting platform in November 2024, we’ve seen strong interest from the market. Even in its early stages, we successfully delivered solutions in Q1 to large employers, including one with over 1,000 employees. We’re on track for a full rollout in Q3, marking a major milestone as we broaden our total addressable market and provide smarter, faster quoting for mid-sized and large employers.”

“As we move forward, we’re accelerating new program development and expanding our broker and TPA network to grow our national footprint. With a robust pipeline and sustained momentum, we expect continued strong growth in Q2 2025. We remain dedicated to delivering exceptional value, innovation, and service as we scale.”

Recent Developments and Business Highlights

  • Partnerships and Collaborations. On March 25, 2025, the Company announced a strategic collaboration with DialCare, a leading provider of telehealth and virtual care solutions. Through this partnership, DialCare’s virtual primary care, therapy, and psychiatry services will be integrated into Health In Tech’s self-funded health plan offerings. Members across the U.S. will gain on-demand access to licensed physicians, therapists and psychiatric providers via phone or video consultations. This collaboration further enhances the Company’s mission to deliver smarter, more accessible healthcare solutions for diverse populations.
  • Appointment of Sanjay Shrestha to Board of Directors. On April 10, 2025, the Company announced the appointment of Sanjay Shrestha to its Board of Directors. Mr. Shrestha brings extensive leadership experience in scaling platform-based businesses and driving growth across the energy and technology sectors. He currently serves as President of Plug Power, having joined the company in 2019 as Chief Strategy Officer. He has played a pivotal role in driving growth and expanding value for both customers and shareholders. As General Manager, he significantly broadened the company’s product portfolio and built out the Energy business to deliver end-to-end solutions—including electrolyzers, liquefiers, and cryogenic systems—while overseeing the development of Plug’s hydrogen production facilities. In addition to his operational expertise, Mr. Shrestha has a strong capital market background, having served as a top-ranked renewables research analyst at Lazard Capital Markets and First Albany Capital. His appointment adds valuable industry and financial expertise to the Board and further strengthens Health In Tech’s strategic vision for long-term growth and market expansion.

Conference Call Details

Health In Tech will host a conference call to discuss the financial results for the first quarter of 2025 on April 14, 2025 at 5:00 p.m. (ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).

A live audio webcast will be available via the Investor Relations page of Health In Tech’s website at https://healthintech.com/. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Non-GAAP Financial Information

This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.

Use of ForwardLooking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

About Health In Tech 

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

 

 

Health In Tech, Inc.

Consolidated Statements of Operations

(Unaudited

Three Months Ended March 31,

2025

2024

Revenues

Revenues from underwriting modeling (ICE)

$2,351,984

$1,784,635

Revenues from fees

5,663,000

3,340,296

    SMR

5,663,000

2,532,922

    HI Card

807,374

Total revenues

8,014,984

5,124,931

Cost of revenues

2,659,585

989,911

Gross profit

5,355,399

4,135,020

Operating expenses

Sales and marketing expenses

1,090,255

1,043,208

General and administrative expenses

3,246,765

1,999,194

Research and development expenses

537,721

760,196

Total operating expenses

4,874,741

3,802,598

Other income (expense):

Interest income

85,366

24,312

Interest expenses

(165,000)

Other income

118,399

Total other income (expense), net

203,765

(140,688)

Income before income tax expense

$684,423

$191,734

Provision for income taxes

(185,831)

(91,198)

Net income

$498,592

$100,536

Net income per share

Basic

$0.01

Diluted

$0.01

 Weighted average common stocks outstanding

Basic

54,619,858

51,769,358

Diluted

56,996,936

51,769,358

 

 

Health In Tech, Inc.

Consolidated Balance Sheets

(Unaudited

March 31, 2025

December 31, 2024

Assets               

Current assets

Cash and cash equivalents

$7,575,037

$7,849,248

  Accounts receivable, net

2,110,601

1,647,103

  Other receivables

3,989,788

500,252

  Deferred offering costs

91,500

  Prepaid expenses and other current assets

1,804,912

787,161

Total current assets

15,571,838

10,783,764

Non-current assets

  Software

4,736,093

3,962,461

  Loans receivable, net

831,994

815,995

  Operating lease – right of use assets

190,275

206,269

Total non-current assets

5,758,362

4,984,725

Total assets

$21,330,200

$15,768,489

Liabilities and stockholders’ equity

Current liabilities

Accounts payable and accrued expenses

$5,478,888

$1,858,840

Income taxes payable

425,556

205,253

Operating lease liabilities – current

69,122

66,881

Other current liabilities

780,045

Total current liabilities

6,753,611

2,130,974

Non-current liabilities

Deferred tax liabilities

294,203

328,676

Operating lease liabilities – non-current

121,595

139,811

Total non-current liabilities

415,798

468,487

Total liabilities

7,169,409

2,599,461

Stockholders’ equity

Common stock, $0.001 par value; Class A Common stock
   150,000,000 shares authorized, 42,973,204 and
   42,914,870 shares issued and outstanding as of
   March 31, 2025 and December 31, 2024, respectively

42,973

42,915

Common stock, $0.001 par value; Class B Common stock
   50,000,000 shares authorized, 11,700,000 shares
   issued and outstanding as of March 31, 2025 and
   December 31, 2024, respectively

11,700

11,700

Additional paid-in capital

9,666,130

9,173,017

Retained earnings

4,439,988

3,941,396

Total stockholders’ equity

14,160,791

13,169,028

Total liabilities and stockholders’ equity

$ 21,330,200

$15,768,489

 

 

Health In Tech, Inc.

Consolidated Statements of Cash Flows

(Unaudited

Three Months Ended March 31,

2025

2024

CASH FLOWS FROM OPERATING ACTIVITIES: 

Net income

$498,592

$100,536

Adjustments to reconcile net income to net cash provided by
(used in) operating activities:

  Amortization expense

135,983

134,787

Provision for potential revenue reduction

780,045

Deferred tax benefits

(34,473)

(60,070)

Amortization of debt discount

165,000

Interest income

(15,999)

(15,999)

Stock-based compensation expense

493,171

Changes in operating assets and liabilities:

Accounts receivable

(463,498)

221,102

Other receivables

(3,489,536)

237,093

Prepaid expenses and other current assets

(1,017,751)

(89,988)

Operating lease right of use assets and liabilities, net

19

624

Accounts payable and accrued expenses

3,420,497

(1,485,329)

Income taxes payable

220,303

112,032

Net cash provided by (used in) operating activities

527,353

(680,212)

CASH FLOWS FROM INVESTING ACTIVITIES:

Development of software

(703,475)

(133,394)

Net cash used in investing activities

(703,475)

(133,394)

CASH FLOWS FROM FINANCING ACTIVITIES:

Payments of deferred offering costs

(98,089)

(243,210)

Net cash used in financing activities

(98,089)

(243,210)

Decrease  in cash and cash equivalents

(274,211)

(1,056,816)

Cash and cash equivalents, beginning of year

7,849,248

2,416,350

Cash and cash equivalents, end of year

7,575,037

1,359,534

Supplemental disclosures of cash flow information:

Cash paid for interest

$-

$-

Cash paid for income taxes

$-

$39,235

Summary of noncash investing and financing activities:

Accrued deferred offering costs included in accounts
   payable and accrued expenses

$33,250

$110,044

Accrued development of software included in accounts
   payable and accrued expenses

$256,140

$9,500

 

Components of Operating Results

Revenues

While our revenue this quarter primarily comes from underwriting activities and program fees associated with customized healthcare plans for small businesses, our growth is driven by delivering solutions that streamline sales processes, enhance service delivery, and shorten the sales cycle for TPAs, MGUs, and brokers. We offer our services through our three subsidiaries. Program services provided by SMR and MGU activities provided by ICE (including eDIYBS) are interdependent, as they cannot function effectively without being combined. Services provided by HI Card is an optional add-on to our other services, and it cannot be offered on a standalone basis. Brokers that utilize the program services on behalf of the small employer provided by SMR and MGU activities provided by ICE, are not obligated to utilize our HI Card service. Currently ICE does not offer underwriting services as a standalone service. In the future, we may consider offering it as a standalone service.

Cost of revenues

Cost of revenues primarily consists of infrastructure costs to operate our platform such as hosting fees and fees paid to various third-party partners for access to their technology, services and amortization expenses of our capitalized internal-use software related to our platform. We mainly outsource captive management services and data services from the third-party companies. Our internal proprietary system seeks to consistently improve underwriting and services results through machine learning and data feeds. The captive management activities include introducing new carriers, conducting due diligence on carriers, conducting feasibility studies to determine the viability to be a stop-loss carrier on the platform, negotiating terms and contracts, coordinating audit requests, managing relationship with unrelated carriers and their regulators and auditor firms to ensure that our risk associated with our service offerings is minimized.

Sales and marketing expenses

Sales and marketing expenses primarily consist of personnel-related costs including salaries, benefits and commissions cost for our sales and marketing personnel. Sales and marketing expenses also include the costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party for sales and customer acquisition.

General and administrative expenses

General and administrative expenses primarily consist of personnel-related costs and related expenses for our executives, finance, legal, human resources, technical support, and administrative personnel as well as the costs associated with professional fees for external legal, accounting and other consulting services, insurance premiums.

Research and development expenses

Research and development expenses primarily consist of personnel-related costs, including salaries and benefits for our research and development personnel. Additional expenses include costs related to the software development, quality assurance, and testing of new technology, and enhancement of our existing platform technology.

Adjusted EBITDA

Adjusted EBITDA represents our earnings from continuing operations before net interest expense, taxes, and depreciation and amortization expense, adjusted to eliminate stock-based compensation expense and public company readiness costs not deemed capitalizable. Adjusted EBITDA is not a measure calculated in accordance with United States Generally Accepted Accounting Principles, or GAAP. We exclude certain non-recurring or non-cash items when calculating Adjusted EBITDA, and we believe this approach provides a more meaningful measure by offering a clearer view of our underlying operational performance.

 

Financial Results Summary

(Unaudited

($ in millions)

Three Months Ended March 31,

2025

2024

% Change

Total revenues

$

8.0

$

5.1

56.4 %

GAAP gross margin

66.8 %

80.7 %

-13.9 %

Income before income tax expense

$

0.7

$

0.2

257.0 %

Adjusted EBITDA

$

1.2

$

0.5

163 %

 

Investor Contact
Investor Relations:
ir@healthintech.com

 

Nature’s Miracle Holding Inc. Announces Up to $2,000,000 Financing

ONTARIO, Calif., April 15, 2025 /PRNewswire/ — Nature’s Miracle Holding Inc. (NMHI) (“Nature’s Miracle” or the “Company”), a leader in vertical farming technology, today announced that on April 11, 2025, that it has successfully arranged financing with Big Lake Capital, LLC (the “Investor”) in the amount of up to $2,000,000 with initial funding of $600,000.  Big Lake Capital, LLC is controlled by Tie “James” Li who is our Chairman and CEO.

Pursuant to the Convertible Promissory Note signed on April 11, 2025, between the Company and Investor, the Investor shall lend to the Company for up to $2,000,000 with the initial tranche of $600,000 which was funded on April 11, 2025. Terms include interest rate of 10% payable monthly and a term of one year. The investor can choose to convert any amount funded plus accrued interest is convertible into shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) at a conversion price equal to $0.198 or 110% of the closing price of the Common Stock on April 11, 2025, the date of initial funding.  As additional consideration, the Investor shall also receive warrants to purchase up to 10,010,101 shares of Common Stock, with an exercise price of $0.198.

About Nature’s Miracle Holding Inc.

Nature’s Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing products and services to growers in the Controlled Environment Agriculture (“CEA”) industry in the U.S.  The Company’s Common Stock trades on the OTC Markets Group, Inc. (“OTC”) under the symbol “NMHI”.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: the intended use of proceeds from the offering; successful launch and implementation of Nature’s Miracle’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in Nature’s Miracle’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; Nature’s Miracle’s ability to develop and launch new products and services; Nature’s Miracle’s ability to successfully and efficiently integrate future expansion plans and opportunities; Nature’s Miracle’s ability to grow its business in a cost-effective manner; Nature’s Miracle’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of Nature’s Miracle’s business model; developments and projections relating to Nature’s Miracle’s competitors and industry; and Nature’s Miracle’s approach and goals with respect to technology.

These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on the OTC; changes in applicable laws or regulations; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which Nature’s Miracle’s operates; the risk that Nature’s Miracle’s and its current and future collaborators are unable to successfully develop and commercialize Nature’s Miracle’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that Nature’s Miracle’s is unable to secure or protect its intellectual property; the possibility that Nature’s Miracle’s may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in Nature’s Miracle’s filings from time to time with the SEC.

Cision Announces $250 Million New Money Financing, Refinancing, Extension of Debt Maturities

CHICAGO, April 15, 2025 /PRNewswire/ — Cision Ltd. (“Cision“), a leading global provider of earned media software and services to public relations and marketing communications professionals, announced today that it has secured commitments for $250 million of new money financing that will provide additional flexibility for the business and facilitate growth, with overwhelming support from existing lenders and noteholders. Cision’s affiliate Castle US Holding Corporation (the “Company“) entered into a commitment letter and joinders thereto (collectively, the “Commitment Letter“), pursuant to which the Company and holders of over 90% of the Company’s outstanding debt (the “Commitment Parties“) agreed to undertake certain financing transactions, as described below (the “Transactions“). The Commitment Parties include approximately 99% of lenders under the Company’s existing senior secured credit facility and approximately 95% of holders of the Company’s existing unsecured notes (the “Existing Notes“). The Transactions provide material benefits to the Company, including (i) raising approximately $250 million of additional liquidity for the Company, (ii) reducing the principal amount outstanding under certain debt facilities, and (iii) extending debt maturities.

“These Transactions reiterate the support of the high-quality institutions that make up our debt investor base” said Guy Abramo, CEO of Cision. “Having secured additional liquidity and extended our debt maturities to 2030 and beyond, we are positioned to execute on our long-term growth strategy.”

This press release contains important information for remaining holders of the Existing Notes regarding an invitation to participate in the Private Notes Exchange (as defined below). You are encouraged to read this press release in its entirety.

Pursuant to the terms of the Commitment Letter, the Commitment Parties have committed to the following Transactions and related actions: (a) to fund, through a combination of new money and exchange of existing debt of the Company, (i) a senior secured first lien first-out term loan in an aggregate principal amount equal to approximately $250 million of new money, plus transaction fees paid in kind (the “First Out Term Loans“), and (ii) a senior secured first lien second-out term loan in an aggregate principal amount equal to an amount sufficient to facilitate the purchase of term loans under the Existing Credit Agreement (as defined below) at a price agreed between the Company and the Commitment Parties and other lenders participating in the Transactions (the “Second Out Term Loans“), (b) to exchange (the “Private Notes Exchange“) all of their Existing Notes for new first lien third-out 10.00% Senior Secured Notes due 2031 (the “Third Out Notes“), to be issued pursuant to a new indenture, and (c) to provide their consent to amend the existing credit agreement, dated as of January 31, 2020 (the “Existing Credit Agreement“), and the existing indenture governing the unsecured notes, dated as of February 5, 2020 (the “Existing Notes Indenture“), to, among other things, eliminate substantially all restrictive covenants therein and make other modifications to facilitate the Transactions. The Commitment Letter also contemplates that the existing revolving lenders will exchange, on a cashless basis, into a senior secured first lien first-out revolving credit facility in an aggregate commitment amount equal to approximately $137 million (the “First Out Revolver” and, collectively with the First Out Term Loans, the Second Out Term Loans and the Third Out Notes, the “Super Priority Debt“).

The First Out Term Loans and First Out Revolver will have a maturity of April 29, 2030, the Second Out Term Loans will have a maturity of May 31, 2030, and the Third Out Notes will have a maturity of June 30, 2031. The Super Priority Debt will be guaranteed on a senior secured basis, jointly and severally, by the guarantors of the Existing Credit Agreement, and will be secured on a first lien basis by substantially all assets of the Company and such guarantors.  

The Company intends to use debt incurred in the Transactions and the related net proceeds to (i) repay permanently in full and terminate all outstanding commitments under that certain bridge credit agreement, dated as of January 30, 2025, (ii) repay and terminate, or cause the repayment and termination in full of, all outstanding commitments and obligations under certain intercompany credit agreements and promissory notes, (iii) facilitate the purchase of term loans under the Existing Credit Agreement pursuant to the terms of the Transactions, (iv) fund the payment of accrued and unpaid interest on the Existing Notes that have been tendered for cancellation in the Private Notes Exchange and the term loans under the Existing Credit Agreement that are being repurchased in the Transactions and (v) pay related transaction fees and for working capital and general corporate purposes.

“Cision is a leading provider of strategic communications, proactively shaping the future of brands and businesses in real time. The critical liquidity provided by the Transactions positions us to continue to support our 75,000+ partners, including 84% of the Fortune 500, to understand, influence and amplify their stories” said Abramo.

Houlihan Lokey served as financial advisor and Milbank LLP served as legal counsel to Cision. Evercore served as financial advisor and Gibson, Dunn & Crutcher LLP served as legal counsel to the Commitment Parties.

The Private Notes Exchange

The Company expects to issue the Third Out Notes to the noteholders that are Commitment Parties (“Committed Noteholders“) pursuant to the Private Notes Exchange on April 22, 2025 (the “Initial Issuance Date“). Holders of the Existing Notes that are not Committed Noteholders are invited to participate in the Private Notes Exchange on the same terms offered to the Committed Noteholders on or before May 12, 2025, 20 business days after the date hereof. Holders who would like to receive more information about the terms of the Private Notes Exchange should contact Cision at Cision@is.kroll.com. Subject in all respects to Cision’s determination and discretion, and in respect of its right to purchase Existing Notes through open market or privately negotiated transactions:

  • Initial Notes. Holders who contact Cision on or prior to April 17, 2025 may be eligible to receive Third Out Notes on the Initial Issuance Date.
  • Additional Fungible Notes. Holders who contact Cision after April 17, 2025 but on or prior to April 29, 2025 may be eligible to receive Third Out Notes on May 2, 2025 (the “Additional Issuance Date“). The Company expects that Third Out Notes issued on the Additional Issuance Date will be fungible with the Third Out Notes issued on the Initial Issuance Date.
  • Additional Non-Fungible Notes. Holders who contact Cision after April 29, 2025 may be eligible to receive Third Out Notes thereafter. However, Third Out Notes issued after May 2, 2025 may not be fungible with Third Out Notes issued on the Initial Issuance Date or the Additional Issuance Date.

The Committed Noteholders, who collectively own approximately 95% of the Existing Notes, have committed to exchange all of their Existing Notes for Third Out Notes. Due to the high levels of committed participation, holders of Existing Notes are cautioned that the Private Notes Exchange may have adverse effects on the liquidity and market price of Existing Notes that are not tendered and accepted pursuant to Private Notes Exchange.

In addition, Existing Notes that are not tendered and accepted pursuant to the Private Notes Exchange will remain outstanding and will be subject to the terms of the Existing Notes Indenture, as amended to, among other things, eliminate substantially all restrictive covenants therein (the “Proposed Amendments“). Holders are cautioned that, if the Proposed Amendments become operative, the elimination or modification of the covenants and other provisions in the Existing Notes Indenture contemplated by the Proposed Amendments will permit the Company and its subsidiaries to take certain actions previously prohibited by the Existing Notes Indenture that could increase the credit risks with respect to the Company, as well as adversely affect the liquidity, market price and price volatility of the Existing Notes or otherwise be adverse to the interests of holders.

The Third Out Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act“), or any other securities laws, and the Third Out Notes cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

This press release is for informational purposes only. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. Holders of the Existing Notes are encouraged to consult their own legal, financial and tax advisers regarding the Private Notes Exchange. 

About Cision

Cision is a global leader in consumer and media intelligence, engagement, and communication solutions. We equip PR and corporate communications, marketing, and social media professionals with the tools they need to excel in today’s data-driven world. Our deep expertise, exclusive data partnerships, and award-winning products – including CisionOneBrandwatch, and PR Newswire – enable over 75,000 companies and organizations, including 84% of the Fortune 500, to see and be seen, understand and be understood by the audiences that matter most.

For media inquiries, please contact:
Cision Public Relations
CisionPR@cision.com

Forward-Looking Statements

This press release contains statements that relate to future events and expectations and, as such, constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These forward-looking statements are not historical facts, but only predictions and generally may be characterized by terminology such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,” “target,” “endeavor,” “seek,” “predict,” “intend,” “strategy,” “plan,” “may,” “could,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements that address activities, events or developments that the Cision or the Company intends, expects, projects, believes or anticipates will or may occur in the future.

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those currently anticipated. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties, many of which will be important in determining the actual future results of Cision, the Company and their subsidiaries and affiliates. These statements are based on current expectations and the current economic environment, and involve a number of risks and uncertainties that are difficult to predict. Actual results could differ materially from those expressed or implied in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date of this press release, and the Company does not undertake any obligation to publicly correct or update any forward-looking statement if the Company later becomes aware that such statement is not likely to be achieved.

 

BRI Prepares Rp3 Trillion for Share Buyback to Sustain Long-Term Performance

JAKARTA, Indonesia, April 14, 2025 /PRNewswire/ — PT Bank Rakyat Indonesia (Persero) Tbk. (BRI) (IDX: BBRI) is carrying out a share buyback as a strategic step to support the employee and corporate share ownership program in relation to the sustainability of BRI’s long-term performance.

BRImo, a financial super app, enables customers to perform various transactions, from online onboarding, payments, purchases, and investments to insurance and financial tracking
BRImo, a financial super app, enables customers to perform various transactions, from online onboarding, payments, purchases, and investments to insurance and financial tracking

Corporate Secretary of BRI, Agustya Hendy Bernadi, stated that the BRI buyback had received approval from the Annual General Meeting of Shareholders (AGMS) held on March 24, 2025, with a maximum amount of Rp3 trillion.

“The buyback will be done through or outside the Stock Exchange, either in stages or all at once, and must be completed no later than 12 (twelve) months after the date of the AGMS,” explained Hendy.

As an initial stage, BRI will conduct the first period of buyback in April 2025 as part of the company’s strategy to enhance investor confidence. The step taken by BRI also considers global and domestic macroeconomic conditions, including the effects of new tariff policies announced by the US President’s administration and uncertainty over the direction of the benchmark rate policy, namely the Federal Funds Rate (FFR).

Hendy added that the decision for the buyback during this period reflects BRI’s strong commitment to safeguarding shareholder interests amid market fluctuations. Furthermore, BBRI’s buyback is also carried out in accordance with applicable regulations, including Article 43 of the Financial Services Authority Regulation (POJK) No. 29 of 2023.

“Through this corporate action, the company has carefully considered current liquidity conditions and financial position, ensuring that the buyback implementation will not disrupt BRI’s financial health,” he stated.

BRI has been conducting buybacks as part of the Employee, and/or Board of Directors and Board of Commissioners Share Ownership Program since 2015. This program is part of the company’s efforts to encourage employee engagement toward the sustainability of the company’s long-term performance improvement.

“BBRI’s buyback is projected to increase the motivation and performance of BRILiaN personnel, enabling optimal achievement of targets and ultimately leading to improved company performance. On the other hand, the implementation of this policy continues to refer to applicable regulations and good corporate governance (GCG) principles,” said Hendy.

For more information about BANK BRI, visit www.bri.co.id

 

 

Covation Biomaterials Announces Launch of BioPTMEG at Chinaplas 2025

SHENZHEN, China, April 14, 2025 /PRNewswire/ — Covation Biomaterials LLC (“CovationBio®“), a biomaterials company with advanced technology in the bio-based materials industry, proudly announces its newest innovation, CovationBio® bioPTMEG, the advanced, sustainable polytetramethylene ether glycol (PTMEG), delivering high performance with significantly lower environmental impact.

BioPTMEG is a bio-based alternative to petroleum-based PTMEG, helping customers reduce their reliance on non-renewable materials and maintain the durability and resilience expected in high performance applications such as spandex, polyurethanes and thermoplastic elastomers.

A few of the superior sustainability benefits offered by CovationBio® bioPTMEG include: 

  • a substantial reduction of greenhouse gas emissions compared to fossil-based incumbents;
  • a product that is 100% bio-based and obtained from annually renewable resources;
  • the use of feedstock such as corncobs which do not compete with primary food sources;
  • a reduced reliance on non-renewable fossil fuel use.
  • Drop-in performance to allow downstream to switch to bio-based raw material without major process change

Mr. Feifeng You, Chairman of CovationBio, stated: “As a force of nature, CovationBio’s vision is to build a sustainable, decarbonized materials industry. To this end, we’re proud to launch CovationBio® bioPTMEG. It uses carbon absorbed by plants from the atmosphere for material creation, improving the quality of life. We’re scaling up production to cut carbon footprints. This is our responsibility to future generations. Through continuous innovation and cooperation, we aim to build a sustainable and regenerative materials industry. We invite all stakeholders to join us in creating a greener, cleaner, and more prosperous world.”

“This drop-in replacement can be seamlessly integrated into existing manufacturing processes and does not require extensive, or even any, product development,” he added

The construction of a plant in Jiangsu Province, Qidong is expected to be mechanically complete toward the end of 2025. Commercial production should begin in the first quarter of 2026.

Those attending Chinaplas may visit the CovationBio® booth at Hall 20, Booth H21 from April 15-18, 2025.
Aligned with this year’s theme, “Transformation, Collaboration, Sustainability,” the team will highlight how CovationBio® bioPTMEG can integrate into customer materials and advance sustainability strategies.

On April 14th 2025, the Global Marketing Director for C4 Platform Dr. Mosha Zhao and the Global Technology Director of CovationBio Dr. Dan Slanac will make the first official introduction to CovationBio® bioPTMEG on the Media Day of Chinaplas 2025 to share the global sustainability commitment of CovationBio and the impact of this new technology. For those interested in learning more, please visit bioPTMEG@covationbio.com.

Disclaimer: The statements regarding product‘s life cycle analysis (LCA) and product performances above are based on tests by CovationBio and True North, an authoritative third party in the US. As the relevant data involves trade secrets, it will only be provided upon legal request in administrative or judicial proceedings. We appreciate your understanding.

About CovationBio®

Founded in 2022, in Newark, Delaware, Covation Biomaterials LLC is a biomaterials company with advanced technology in the bio-based materials industry, offering a product portfolio of high-performance, sustainable solutions.

The company builds on its rich DuPont legacy of groundbreaking scientific innovation and continues to deliver novel solutions at scale across multiple industries, including apparel, carpeting, cosmetics, food, and packaging. Through product lines such as Sorona®, Susterra® and Zemea®, the mission of Covation Biomaterials is to deliver building blocks that will enable customers to provide bio-based products accessible to everyone. Covation, Covation Biomaterials, Sorona, Susterra, and Zemea are trademarks of Covation Biomaterials™ or its affiliates. For more information about Covation Biomaterials, please visit CovationBio.com and follow on WeChat, LinkedIn, Instagram, and Facebook.